Visual Outcomes and Patient Satisfaction in Subjects With Stable Open-angle Glaucoma Undergoing Concurrent Minimally Invasive Glaucoma Surgery and IOL Implantation With an Extended-depth-of-focus IOL

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study is designed to determine how well patients with glaucoma can see following cataract surgery with a special type of lens called an extended-depth-of-focus (EDOF) lens. This lens is intended to reduced the patients need for glasses following cataract surgery. Patients will also undergo a minimally invasive type of glaucoma surgery using a special type of stent to reduce eye pressure, with the goal of better glaucoma control and the reduction in the need for medications to control eye pressure.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 45
Healthy Volunteers: f
View:

• Male or female subjects 45 years of age or older

• A visually significant age-related cataract in both eyes

• Diagnosis of mild OAG

‣ VF characteristics consistent with glaucoma with mean deviation not worse than -6.00 dB and without fixation threatening scotoma AND/OR with nerve abnormalities consistent with glaucoma (rim notching, rim thinning, disc hemorrhage, nerve fiber layer loss)

⁃ Medicated IOP ≤25 mmHg on 1-3 hypotensive medications

• Glaucoma must be judged as stable by investigator based on review of subject medical records

‣ Stable VF at least 1 year prior to surgery

⁃ Stable nerve fiber layer at least 1 year prior to surgery

⁃ IOP stable on current medication regimen at least 3 months prior to surgery

• Shaffer grade of ≥ III in all angle quadrants

• Potential of best corrected visual acuity at distance in the investigator's judgement of at least 0.1 logMAR (20/25) postoperatively

• Able and willing to comply with follow up visits

• Understands and signs the informed consent

• Both eyes of the subject should undergo surgery within 21 days of each other to ensure adequate timing for final visit window of 90 days ± 21 days post operatively

Locations
United States
Arkansas
Vold Vision P.L.L.C.
RECRUITING
Fayetteville
Time Frame
Start Date: 2022-12-07
Estimated Completion Date: 2025-05-01
Participants
Target number of participants: 25
Treatments
Experimental: Treatment Group
Subjects implanted with the Vivity IOL undergoing concurrent implantation of the Hydrus Microstent
Sponsors
Leads: Vold Vision P.L.L.C
Collaborators: Alcon Research

This content was sourced from clinicaltrials.gov